Crown Bioscience

MAY 4, 2021

Among the 180+ cancer drugs approved by the FDA since 1995, only 14 have been approved for pediatric use, with another 26 used off-label (i.e. used in a way that is not described in the license), and only three drugs have been approved exclusively for use in children.

Research 52

Research Pharmaceutical Companies Licensing Licensing 52

The Pharma Data

JANUARY 17, 2021

In particular, two new drugs developed by Hanmi Pharmaceutical Co., “Rolontis,” a treatment for neutropenia that had its technology licensed out to Spectrum Pharmaceuticals, Inc. and “Oraxol,” which was licensed out to Athenex, Inc. Hanmi Pharmaceutical Co.,

FDA Approval 52

FDA Approval FDA Pharmaceuticals Clinical Trials 52

Drug Target Review

FEBRUARY 1, 2024

But commitment to neuroscience drug development is critically important given the significant unmet medical needs and the ways in which patients, caregivers, and families suffer. As soon as drug developers can begin to develop conviction, momentum increases. It’s a great example of how our model works.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

Molecule Blog

JANUARY 9, 2023

IP-NFTs upgrade our legacy intellectual system by unifying IP (patents, legal), underlying data (through decentralized storage and access control), and economics (royalties, license fees, sales) into one programmable, transactable, digital unit. ‍ How will IP-NFTs enable drug development in the future?

Research 52

Research Licensing Licensing Science 52

Drug Discovery World

OCTOBER 16, 2023

From the Beatson Institute for Cancer Research in Glasgow, to Edinburgh Drug Discovery in the University of Edinburgh’s Institute for Genetics and Cancer (IGC). At ELRIG’s Scottish Research and Drug Development Forum meeting, DDW’s Diana Spencer provided a snapshot of drug discovery in Scotland.

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189

The Pharma Data

DECEMBER 9, 2020

Under its ongoing collaboration and license agreement, Crescendo’s proprietary transgenic platform and engineering expertise is being used to build Humabody ® -based therapeutics against certain targets selected by Takeda. This is the sixth technical milestone achieved by Crescendo in its collaboration with Takeda.

Licensing 52

Licensing Licensing Pharmaceutical Companies Engineering 52

Drug Discovery World

AUGUST 3, 2023

There are also three synthetic cannabis-related drug products, which are Marinol (dronabinol), Syndros (dronabinol), and Cesamet (nabilone). Even still, these approved drug products require a licensed healthcare provider’s prescription.

Clinical Trials 130

Clinical Trials Regulations Production FDA 130

Drug Discovery World

MARCH 7, 2023

She has over 15 years’ experience in corporate finance and restructurings, mergers and acquisitions, joint ventures and intellectual property licensing. Hu was formerly a consultant at McKinsey & Company where she advised pharmaceutical companies on strategic, operational and organizational issues.

International 246

International Science Pharmaceuticals DNA 246

Molecule Blog

AUGUST 19, 2021

In drug development however, when a therapeutic is discovered, or research becomes more akin to product development, the source of funding must change. These grants are utilised by researchers to get to the point of developing a potentially life-saving therapeutic. And this is the best-case scenario. for patents)?

Research 52

Research Licensing Licensing Drug Development 52

Drug Discovery World

OCTOBER 10, 2022

Will an expansion in the use of effective digital biomarkers help improve the productivity of drug development in neuroscience? Increasingly, digital biomarkers are becoming more effectively used in the discovery and development of drugs that act in the central nervous system. The solution provided by digital biomarkers.

Drug Development 130

Drug Development Clinical Trials Drugs Trials 130

The Pharma Data

JANUARY 27, 2021

The Company’s validated, proprietary F.I.R.S.T technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

The Pharma Data

DECEMBER 8, 2020

AbCellera’s AI-powered antibody discovery platform speeds the otherwise lengthy and grueling process by analyzing the database of natural immune systems to find antibodies that can be developed into drugs. Tackle the toughest problems in drug development.” The promise to partners is to “move quickly. Reduce cost.

RNA 52

RNA Protein Expression Therapies Disease 52

The Pharma Data

NOVEMBER 6, 2020

With the opinions expressed at the Advisory Committee and the data presented, the FDA will continue the review process with a decision on whether to approve the aducanumab Biologics License Application by March 7, 2021. . Biogen licensed aducanumab from Neurimmune under a collaborative development and license agreement.

Disease 40

Disease FDA Clinical Trials Licensing 40

The Pharma Data

JANUARY 24, 2021

The company has established a diversified R & D pipeline comprising 27 innovative drug candidates and 2 biosimilars, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases.

FDA 52

FDA Clinical Trials Trials Treatment 52

Drug Discovery World

MARCH 6, 2024

Precision neuroscience has similar potential to revolutionise neurological drug development, but it requires a different way of thinking about disease than we usually apply in oncology. All this is of huge interest when you’re putting a new drug on the market and working inside an outcomes-based remuneration model.

Clinical Trials 162

Clinical Trials Pharmaceutical Companies Disease Trials 162

The Pharma Data

OCTOBER 29, 2020

Biogen licensed aducanumab from Neurimmune under a collaborative development and license agreement. have collaborated on the development and commercialization of aducanumab globally. is a leading global pharmaceutical company headquartered in Japan. Since October 2017 Biogen and Eisai Co., About Eisai Co.,

Marketing 40

Marketing Disease Clinical Trials Treatment 40

The Pharma Data

DECEMBER 9, 2020

Biogen licensed aducanumab from Neurimmune under a collaborative development and license agreement. have collaborated on the development and commercialization of aducanumab globally. is a leading global pharmaceutical company headquartered in Japan. Since October 2017 Biogen and Eisai Co., About Eisai Co.,

Clinical Trials 40

Clinical Trials Drugs Disease Licensing 40

Advarra

AUGUST 10, 2023

The Orphan Drug Act creates incentives for developing orphan drugs to treat such diseases. Operation Warp Speed for Rare Diseases looks to accelerate both drug development and approval. The post Operation Warp Speed for Rare Diseases: Expected Boom in Drug Development and Approval appeared first on Advarra.

Drug Development 52

Drug Development Disease Engineering Therapies 52

Drug Discovery World

MAY 11, 2023

The drug has already shown particular promise in ovarian cancer in a first-in-human, Phase I trial led by researchers at the ICR and The Royal Marsden NHS Foundation Trust. Algok Bio’s exclusive license agreement with BTG grants the former the rights to develop and commercialise idetrexed worldwide.

Trials 130

Trials Small Molecule Drugs Pharmaceutical Companies 130

The Pharma Data

SEPTEMBER 8, 2020

About the Janssen Pharmaceutical Companies of Johnson & Johnson At Janssen, we’re creating a future where disease is a thing of the past. Risk Factors,” and in the company’s most recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

SEPTEMBER 8, 2020

About the Janssen Pharmaceutical Companies of. We’re the Pharmaceutical Companies of. D “Risk Factors” in the company’s Annual Report on Form 20-F for 2019 and as set out in GSK’s “Principal risks and uncertainties” section of the Q2 Results and any impacts of the COVID-19 pandemic.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

Altus Drug Development

MAY 31, 2022

Drugs introduced to the body through oral delivery are absorbed by the stomach, intestine, or gastrointestinal tract. Common examples of oral drug delivery systems include tablets and capsules. What is formulation drug development? Drug formulation is the process of creating licensed pharmaceutical products.

Pharmaceuticals 52

Pharmaceuticals Drug Development Production Pharmaceutical Companies 52

Codon

FEBRUARY 13, 2024

Phage-based products have been licensed for use as antibacterial agents in the sanitation , food production , and animal health industries. The weakened dose of phages helped bacteria develop resistance, and the trial became yet another study that provided evidence phages are safe, but little more.

Therapies 138

Therapies DNA Virus Clinical Trials 138

NIH Director's Blog: Drug Development

FEBRUARY 27, 2018

More than 90 percent of that contributory research was basic—that is, related to the discovery of fundamental biological mechanisms, rather than actual development of the drugs themselves. Previous attempts to quantify the contribution of federal funding to new drug development had looked primarily at patents.

Research 52

Research Science FDA Pharmaceutical Companies 52

Molecule Blog

MARCH 17, 2023

The university then licenses the IP to an existing pharmaceutical company or a biotech startup, which takes on Investigational New Drug (IND) enabling studies. Funding typically comes from a mix of government agencies, venture capitalists (VCs), and pharmaceutical companies.

Engineering 52

Engineering Research Government Clinical Trials 52

The Pharma Data

OCTOBER 27, 2020

Novartis has been granted an option to in-license global rights of MP0420 and MP0423 – multi-targeted direct-acting antiviral therapeutic candidates demonstrating potential efficacy against COVID-19. The company has compounds in various stages of clinical and preclinical development with a focus on oncology.

Therapies 52

Therapies Virus Treatment Clinical Trials 52

The Pharma Data

NOVEMBER 15, 2020

a publicly traded biopharmaceutical company, from 2012 to December 2019, managing its international, legal, quality, intellectual property and compliance functions, after serving in other executive roles at Acorda starting in 2004. drug development initiative from 2012 to February 2019. Before joining Acorda, Ms.

Clinical Trials 40

Clinical Trials Trials Production International 40

Agency IQ

OCTOBER 27, 2023

Date What’s Happening Explanation Source October 31 FDA deadline on Florida drug importation plan The FDA has said in court filings that it plans to make a ruling on Florida’s prescription drug importation plan by October 31. The following PDUFA dates were obtained from publicly available sources.

FDA 40

FDA Science Regulations Production 40

Drug Discovery World

NOVEMBER 10, 2023

AH : I am Chief Business Officer for Antibody Analytics, a collaborative immunology CRO, specialising in supporting immunotherapy developers at the discovery to pre-clinical stages of the drug development process. I have now been with Antibody Analytics for three and half years. MT: Who or what inspires you?

Molecular Biology 147

Molecular Biology Clinical Trials Licensing Licensing 147

The Pharma Data

DECEMBER 15, 2020

(NASDAQ/TASE: BLRX) is a late clinical-stage biopharmaceutical company focused on oncology. The Company’s business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization.

Clinical Trials 52

Clinical Trials Trials Therapies Treatment 52

The Pharma Data

DECEMBER 30, 2020

In short, the advisory committee did not vote to recommend the drug to the agency, which has a PDUFA date of March 7, 2021 to decide whether to approve the aducanumab Biologics License Application (BLA). Biden Administration and drug pricing. BioMarin Pharmaceutical’s Roctavian for hemophilia B.

Vaccine 52

Vaccine FDA Trials Therapies 52